(Total Views: 360)
Posted On: 06/22/2019 7:29:24 PM
Post# of 155051
Welcome to the board! I can’t answer your pending patent questions or enlighten you on the patent protect period.
I’m sure someone will chime in with more knowledge and you may already know this, but CYDY owns CCR5 mechanism of action (MOA) in cancer through the ProstaGene acquisition last fall. Dr. Pestell filed for these upon his discovery when working with Maraviroc and the other CCR5 (sorry don’t recall off the top of my head), so even if other drugs are approved in cancer based on CCR5 MOA, CYDY will be involved. Dr. Pestell also has another patent pending with Dr. Cristofanilli for CTC I believe. There may be a post here that has these patents listed by filing number.
Should be a good 12 years post approval if all or even some the CCR5 indications work with Leronlimab. So far HIV, cancer, GvHD, NASH and MS look pretty promising. There are many others that haven’t been tested yet with Leronlimab in preclinical or clinical trials that may add to the already impressive list.
I’m sure someone will chime in with more knowledge and you may already know this, but CYDY owns CCR5 mechanism of action (MOA) in cancer through the ProstaGene acquisition last fall. Dr. Pestell filed for these upon his discovery when working with Maraviroc and the other CCR5 (sorry don’t recall off the top of my head), so even if other drugs are approved in cancer based on CCR5 MOA, CYDY will be involved. Dr. Pestell also has another patent pending with Dr. Cristofanilli for CTC I believe. There may be a post here that has these patents listed by filing number.
Should be a good 12 years post approval if all or even some the CCR5 indications work with Leronlimab. So far HIV, cancer, GvHD, NASH and MS look pretty promising. There are many others that haven’t been tested yet with Leronlimab in preclinical or clinical trials that may add to the already impressive list.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
